Press Release - HBM Holdings

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release

Press Release In the News Image Library Awards & Recognitions

January 10, 2025

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

Cambridge, MA, Rotterdam, NL, Shanghai, CN — January 10, 2025 Harbour BioMed (HKEX: 02142, the “Company”), a global biophar...
View more
November 15, 2024

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceuti...
View more
November 08, 2024

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Cambridge, MA, Rotterdam, NL, Suzhou, CN – November 8, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutic...
View more
October 10, 2024

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

Cambridge, MA, Rotterdam, NL, Suzhou, CN — October 9, 2024 Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...
View more
September 14, 2024

Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Cambridge, MA, Rotterdam, NL, Suzhou, CN — September 14, 2024 Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...
View more
August 28, 2024

Harbour BioMed Announces 2024 Interim Results

Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and c...
View more
July 26, 2024

Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Cambridge, MA, Rotterdam, NL, Suzhou, CN — July 25, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more
July 19, 2024

Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 19, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more
June 27, 2024

Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 27, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more
May 23, 2024

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) , a global biotechnology company providing a total solution from “Idea ...
View more